×

Presentation of IPH4102 rationale and Phase I protocol to be presented at the upcoming EORTC CTCL meeting

MARSEILLE, France, Sept. 7, 2015 (GLOBE NEWSWIRE) -- Innate Pharma SA (the "Company" - Euronext Paris: FR0010331421 - IPH) today announced that Professor Martine Bagot, Head of the Dermatology Department at the Saint-Louis Hospital in Paris and co-discoverer of the target KIR3DL2, will present the rationale of IPH4102, a first-in-class anti-KIR3DL2 monoclonal antibody for the treatment of CTCL, as well as the protocol of the upcoming Phase I trial at the EORTC cutaneous lymphoma task force meeting (September 25-27, 2015 in Turin, Italy).

Presentation title: "A novel targeted immunotherapy for CTCL: anti-KIR3DL2 mAb IPH4102 is potent and safe in non-clinical studies"
Session Name: Neil-Smith memorial lecture
Date: Saturday, September 26, 2015
Presentation Time: 12:30 AM - 1:00 PM

The presentation will be available at its public presentation on Innate Pharma's website.

****
Innate Pharma will host a Key Opinion Leader luncheon to discuss
Cutaneous T-cell Lymphoma on Friday, October 2, 2015, in New York.

Youn H. Kim, MD, Professor of Dermatology,
Director of Multidisciplinary Cutaneous Lymphoma Program and Medical Director of Photopheresis Service at the Stanford Medical Center will lead the discussion.

This event is intended for institutional investors and sell-side analysts. To reserve a place, please contact Mac MacDonald at 212-915-2567 or via e-mail at mac@lifesciadvisors.com. A live webcast and subsequent replay of the event will be available at http://lifesci.rampard.com/20150929

****

About IPH4102:

KIR3DL2 is an inhibitory receptor of the KIR family, normally expressed on a subset of normal NK cells and specifically expressed in most subtypes of the orphan indication of CTCL. This group of rare cutaneous lymphomas of T lymphocytes has a poor prognosis with few therapeutic options at advanced stages.

IPH4102 is a first-in-class anti-KIR3DL2 humanized cytotoxic antibody, designed to selectively deplete CTCL cancer cells. Potent antitumor properties of IPH4102 were shown against human CTCL cells in vitro and in vivo in a mouse model of KIR3DL2+ tumors, in which IPH4102 reduced tumor growth and improved survival. The efficacy of IPH4102 was further evaluated in laboratory assays using the patients' own natural killer (NK) cells against their primary tumor samples in presence of IPH4102. These latter studies were performed in patients with Sézary Syndrome, the leukemic form of CTCL with the worst prognosis. In these experiments, IPH4102 selectively and efficiently induced killing of the patients' CTCL cells. These results were published in Cancer Research in 2014. A Phase I trial is expected to start in 2015.

IPH4102 was granted orphan drug status in the European Union for the treatment of CTCL. Biomarker tools are being developed in parallel to monitor KIR3DL2 expression in patients.

About Innate Pharma:

Innate Pharma S.A. is a biopharmaceutical company discovering and developing first-in-class therapeutic antibodies for the treatment of cancer and inflammatory diseases.

Its innovative approach has translated into major alliances with leaders in the biopharmaceutical industry such as Bristol-Myers Squibb, AstraZeneca and Novo Nordisk A/S.

The Company has two clinical-stage programs in immuno-oncology, a new therapeutic field that is changing cancer treatment by enhancing the capability of the body's own immune cells to recognize and kill cancer cells. Innate Pharma's science also has potential in chronic inflammatory diseases.

Listed on Euronext-Paris, Innate Pharma is based in Marseille, France, and had 107 employees as at March 31, 2015.

Learn more about Innate Pharma at www.innate-pharma.com.

Practical Information about Innate Pharma shares:

ISIN code
Ticker code
FR0010331421
IPH

Disclaimer:

This press release contains certain forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. For a discussion of risks and uncertainties which could cause the company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the Document de Reference prospectus filed with the AMF, which is available on the AMF website or on Innate Pharma's website.

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.

For additional information, please contact:

Innate Pharma ATCG Press
Laure-Hélène Mercier
Director, Investor Relations
Tel.: +33 (0)4 30 30 30 87
Marie Puvieux (France)
Mob: +33 (0)6 10 54 36 72
Jean-Medhi Grangeon (ROW)
Mob: +33 (0)6 62 22 00 24
investors@innate-pharma.com presse@atcg-partners.com

150907 IPH EORTC IPH4102 http://hugin.info/155662/R/1950059/708869.pdf

HUG#1950059

Source: INNATE PHARMA